



<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTY DOCKET NO.</b> 20784/5		<b>SERIAL NO.</b> 09/745,833	
				<b>APPLICANT(S):</b> Demuth et al.			
				<b>FILING DATE:</b> November 21, 2000		<b>ART UNIT:</b> Not yet Assigned	
<b>UNITED STATES PATENT DOCUMENTS</b>							
EXAM. INITIAL	CLASS	DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
CMK	AA	5,433,955	7-18-95	Bredehorst, et al.	424	94.3	
/	AB	5,614,379	3-25-97	MacKellar	435	68.1	
CMK	AC	5,624,894	4-29-97	Bodor	514	2	
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
CMK	BA	9308259 A2	4/29/93	WO	C12N		
/	BB	9511689	5/4/95	WO	A61K	37/00	
/	BC	9745117	12/4/97	WO	A61K	31/435	
CMK	BD	19616486	10/30/97	DE	A61K	39/395	
<b>OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)</b>							
CMK	CA	J. Lin et al.: "Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-0-hydroxylamine peptidomimetics" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, Bd. 95, November 1998 (1998-11), Seiten 14020-14024, XP002117450 WASHINGTON US Seite 14023, rechte Spalte, Absatz 3 – Seite 14024, linke Spalte, Absatz 1					
/	CB	KOROM, S., DEMEESTER, I., STADLBAUER, T.H.W., CHANDRAKER, A., SCHAUB, M., SAYEGH, M.H., BELYAEV, A., HAEMERS, A., SCHARPE, S., KUPIEC-WEGLINSKI, J.W., Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients, Transplantation 63, 1495 (1997)					
/	CC	TANKA, S., MURAKMI, T., HORIKAWA, H., SUGIURA, M., KAWASHIMA, K., SUGITA, T., Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. 19, 15 (1997)					
/	CD	MENTLEIN, R., DAHMS, P., GRANDT, D., KRUGER, R., proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 49, 133 (1993)					
CMK	CE	WETZL, W., WAGNER, T., VOGEL, D., DEMUTH, H.-U., BALSCHUN, D., Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes. Neuropeptides, 31, 41 (1997)					
<b>Examiner:</b> 				<b>Date:</b> 6/10/02			

FORM PTO-1449  
SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT



ATTY DOCKET NO.

20784/5

SERIAL NO.

09/745,883

APPLICANT(S): Demuth et al.

FILING DATE:  
December 21, 2000

ART UNIT:  
Not yet Assigned

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)


CMK	CF	WAKSELMAN, M., NGUYEN, C., MAZALEYRAT, J.-P., CALLEBAUT, C., KRUST, B., HOVANESSIAN, A.G., Inhibition of HIV-1 infection of CD 26+ but not CD26-cells by a potent cyclopeptidic inhibitor of the DPP IV activity of CD 26. Abstract P 44 of the 24th European Peptide Symposium 1996.
-----	----	---

Examiner:

*Chen*

Date:

6/10/02



RECEIVED

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 20784/5		SERIAL NO. 09/745,883	
				APPLICANT(S): Demuth et al.			
				FILING DATE: 12/21/00		ART UNIT: 1614	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
CIR	CX	WILLMS, B. et al., Gastric Emptying, Glucose Response, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients. <i>JCEM</i> 81:327-332 (1996)					

#1012551 v\1 - hoferma - p@f01!.doc - 20784/1

6/2/02



RECEIVED  
 MAY 24 2001  
 TECH CENTER 1600/2900

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY DOCKET NO.

20784/5

SERIAL NO.

09/745,883

APPLICANT(S): Demuth et al.

FILING DATE:

12/21/00

ART UNIT:

1614

UNITED STATES PATENT DOCUMENTS


EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPR
CMK	AD	2,961,377	11-1960	Shapiro et al.	167	65	
	AE	3,960,949	6-1976	Ahrens et al.	260	564 B	
	AF	4,935,493	6-1990	Bachovchin et al.	530	331	
	AG	5,512,549	4-1996	Chen et al.	514	12	
CMK	AH	6,006,753	12-1999	Efendic	128	898	8-21-97

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
CMK	BE	0 658 568 A1	12/2/94	EPO	C07K	14/605	Y
	BF	EP 0 708 179 A2	10/13/95	EPO	C12N	15/16	Y
	BG	WO 97/40832	11/6/97	PCT	A61K	31/425	Abstract only
	BH	WO 95/15309	6/8/95	PCT	C07D	207/16	Y
	BI	JP 4334357 A2	11/20/92	JP	C07C	233/57	Abstract only
	BJ	WO 95/29691	11/09/95	PCT	A61K	031/675	Y
	BK	WO 98/22494	5/28/98	PCT	C07K	005/00	Y
	BL	WO 00/53171	9-14-00	PCT	A61K	31/155	Y
	BM	FR 2696740	10-13-92	FR	C07D	207/404	N
	BN	FR 2085665	3-3-71	FR	A61K	27/00	N
	BO	DT 25 42598 A1	10-11-74	DE	C07C	129/16	N
CMK	BP	DD 296 075	11-21-91	DD	C07D	295/04	N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CMK	CG	Campbell, I.W., Sulphonylureas and metformin: efficacy and inadequacy. 3:33-51 (1990).
CMK	CH	Mercla Index, 11 <sup>th</sup> Edition, Page 934
CMK	CI	Martindale the Extra, Pharmacopoeia, Page 1619

RECEIVED  
MAY 24 2001  
TECH CENTER 1600/2900

FORM PTO		ATTY DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT		20784/5	09/745,883
		APPLICANT(S): Demuth et al.	
		FILING DATE:	ART UNIT:
		12/21/00	1614
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
CK	CJ	ARAI, H. ET AL: "Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase" CHEMICAL AND PHARMACEUTICAL BULLETIN., Bd. 41, Nr. 9, 1993 pgs 1583-1588	
	CK	AMASHEH, S. et al., Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in <i>Xenopus Laevis</i> oocytes. <i>J. Physiol.</i> 504, 169-174 (1997)	
	CL	CHEMICAL ABSTRACTS, vol. 115. No. 15, 14. Oktober 1991 (1991-10-14) Columbus, Ohio, US; abstract no. 149947q, SCHOEN EKKEHARD ET AL: "Dipeptidyl peptidase IV in the immune system.Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes" Seite 37; XP002114197 Zusammenfassung & BIOL. CHEM. HOPPE-SEYLER, Bd. 372, Nr. 5, 1991, Seiten 305-311,	
	CM	CHEMICAL ABSTRACTS, vol. 126, no. 2, 13. Januar 1997 (1997-01-13) Columbus, Ohio, US; abstract no. 16161j, STOECKEL A. ET AL: "Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides" Seite 241; XP002114198 Zusammenfassung & PEPT: CHEM., STRUCT.BIOL., PROC.AM.PEPT.SYMP., Nr. 14, 1995, Seiten 709-710,	
	CN	CHEMICAL ABSTRACTS, vol. 118, no. 25, 21. Juni 1993 (1993-06-21) Columbus, Ohio, US; abstract no. 255342k, Seite 933; XP002114199 Zusammenfassung & JP 04 334357 A (FUJEREBIO INC) 20. November 1992 (1992-11-20)	
	CO	THORENS, B et al., Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM. <i>Diabetes</i> 42:1219-1225 (1993)	
	CP	ORSKOV C. et al., Proglucagon Products in Plasma of Noninsulin-dependent Diabetics and Nondiabetic Controls in the Fasting State and After Oral Glucose and Intravenous Argine. <i>J. Clin. Invest.</i> 87:415-423 (1991)	
	CQ	PAULY, R. et al., Improved Glucose Tolerance in Rats Treated with the Dipeptidyl Peptidase IV (CD26) Inhibitor ILE-Thiazolidide. <i>Metabolism</i> 48:385-389 (1999)	
	CR	WINSLOW, R., Novartis Drug Alters Picture for Diabetes. <i>Wall Street Journal</i> , Wed. Dec. 27, 2000, p. B2.	
	CS	HENDRICK, G.K. et al., Glucagon-Like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats. <i>Metabolism</i> Vol. 42, No. 1, pg 1-6 (Jan. 1993)	
	CT	DEACON, C. et al., Degradation of Glucagon-Like Peptide-1 by Human Plasma in yeilds Vitro an N-Terminally Truncated Peptide that is a Major Endogenous Metabolite in Vivo. <i>JCEM</i> 80:952-957, (April 25, 1995)	
	CU	HOFFMAN, T. et al., Inhibition of Dipeptidyl Peptidase IV (DPIV) by anti-DP IV antibodies and non-substrate X-X-Pro- Oligopeptides Ascertained by Capillary Electrophoresis. <i>Journal of Chromatography A</i> , 716 355-362 (1995)	
	CV	NAUCK, M.A. et al., Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (Non-insulin-dependent) Diabetic Patients. <i>Diabetologia</i> 36:741-744 (1993)	
CK	CW	GUTNIAK, M. K. et al., Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM. <i>Diabetes Care</i> 17:1039-1044, (Sept. 1994)	
Examiner:		Date:	